Company Description
ImmunityBio, Inc., a vertically-integrated commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune system to defeat cancers and infectious diseases.
Its platforms for the development of biologic product candidates include cytokine fusion proteins, vaccine vectors, and cell therapies.
The company’s platforms have generated nine first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors.
Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors.
The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. The company is based in San Diego, California.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 680 |
| CEO | Richard Adcock |
Contact Details
Address: 3530 John Hopkins Court San Diego, California 92121 United States | |
| Phone | 844 696 5235 |
| Website | immunitybio.com |
Stock Details
| Ticker Symbol | IBRX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001326110 |
| CUSIP Number | 45256X103 |
| ISIN Number | US45256X1037 |
| Employer ID | 43-1979754 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Richard Gerald Adcock | President, Chief Executive Officer and Director |
| Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.Sc. | Executive Chairman of the Board and Global Chief Scientific and Medical Officer |
| David C. Sachs | Chief Financial Officer |
| Dr. Barry J. Simon M.D. | Chief Corporate Affairs Officer and Director |
| Regan J. Lauer | Chief Accounting Officer |
| Dr. Enrique Diloné Ph.D., RAC | Chief Technology Officer |
| Jason R. Liljestrom J.D. | General Counsel and Corporate Secretary |
| Sarah Singleton | Chief Communications Officer and Head of Patient Advocacy |
| Dr. Leonard S. Sender M.D. | Chief Medical Officer of Liquid Tumors and Cell Therapy |
| Dr. Sandeep K. Reddy M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 19, 2025 | 8-K | Current Report |
| Mar 3, 2025 | 10-K | Annual Report |
| Mar 3, 2025 | 8-K | Current Report |
| Feb 13, 2025 | 8-K | Current Report |
| Feb 7, 2025 | 8-K | Current Report |
| Dec 12, 2024 | 424B5 | Filing |
| Dec 11, 2024 | 8-K | Current Report |
| Dec 10, 2024 | 8-K | Current Report |
| Dec 10, 2024 | 424B5 | Filing |
| Nov 19, 2024 | 8-K | Current Report |